斑蝥酸钠注射液联合化疗治疗晚期非小细胞肺癌的临床观察  

Clinical Observation of Cantharis Acid Sodium Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer

作　　者：刘国建[1] 李娟[1] 王朝霞[1] 王科明[1] 

机构地区：[1]南京医科大学第二附属医院肿瘤科,江苏南京210011

出　　处：《肿瘤基础与临床》2015年第5期416-418,共3页journal of basic and clinical oncology

摘　　要：目的观察斑蝥酸钠注射液联合化疗治疗晚期非小细胞肺癌(NSCLC)的近期疗效和毒副反应。方法60例经病理学证实的晚期NSCLC患者随机均分为2组,每组30例,治疗组30例患者接受多西他赛加顺铂配合斑蝥酸钠注射液治疗,对照组30例患者仅接受单纯化疗,方案同治疗组,并比较观察2组的近期疗效和毒副反应。结果治疗组总有效率为63.3%,高于对照组的40.0%(P<0.05);治疗组主要毒副反应总发生率为76.7%,明显低于对照组的110.0%(P<0.05)。结论斑蝥酸钠注射液联合多西他赛加顺铂化疗治疗晚期NSCLC不仅能提高化疗疗效,还能降低化疗毒副反应,值得临床进一步推广。Objective To observe the clinical efficacy and toxicities of cantharis acid sodium combined with chemotherapy in the treatment of advanced non-small cell lung cancer（ NSCLC）. Methods Sixty patients with ad-vanced NSCLC were randomly divided into the control group（30 patients）and the treatment group（30 patients）. All the patients of the two groups were given with docetaxel plus cisplatin regimen chemotherapy,and 30 patients of the treatment group were given with cantharis acid sodium injection treatment at the same time. After the treatment, the recent clinical efficacy and toxicities were compared. Results The overall response rate was 63. 3% in the treatment group,while was 40. 0% in the control group（P〈0. 05）. The major treatment-related toxicities were my-elosuppression,nausea and vomiting,the overall incidence rate of the treatment group was significantly lower than that of the control group（76. 7% vs 110. 0%,P〈0. 05）. Conclusion Cantharis acid sodium combined with do-cetaxel plus cisplatin regimen chemotherapy in the treatment of advanced NSCLC can improve the recent clinical ef-ficacy and safety.

关 键 词：晚期非小细胞肺癌 斑蝥酸钠注射液 多西他赛 顺铂 

分 类 号：R734.2[医药卫生—肿瘤] R730.59[医药卫生—临床医学]